Literature DB >> 31522867

An imaging-based risk calculator for prediction of conversion to psychosis in clinical high-risk individuals using glutamate 1H MRS.

Lawrence S Kegeles1, Adam Ciarleglio2, Pablo León-Ortiz3, Francisco Reyes-Madrigal3, Jeffrey A Lieberman1, Gary Brucato1, Ragy R Girgis1, Camilo de la Fuente-Sandoval4.   

Abstract

Risk calculators for prediction of conversion of Clinical High-Risk (CHR) individuals to syndromal psychosis have recently been developed and have generated considerable clinical use and research interest. Predictor variables in these calculators have been clinical rather than biological, and our goal was to incorporate a neurochemical imaging measure into this framework and assess its impact on prediction. We combined striatal glutamate 1H MRS data with the SIPS symptoms identified by the Columbia Risk Calculator as having the greatest predictive value in order to develop an imaging-based risk calculator for conversion to psychosis. We evaluated the calculator in 19 CHR individuals, 7 (36.84%) of whom converted to syndromal psychosis during the 2-year follow up. The receiver operating characteristic (ROC) curve for the logistic model including only striatal glutamate and visual perceptual abnormalities showed an AUC = 0.869 (95% CI = [0.667, 1.000]) and AUCoa = 0.823, with sensitivity of 0.714, specificity of 0.917, positive predictive value of 0.833, and negative predictive value of 0.846. These results represent modest improvements over each of the individual ROC curves based on either striatal glutamate or visual perceptual abnormalities alone. The preliminary model building and evaluation presented here in a small CHR sample suggests that the approach of incorporating predictive imaging measures into risk classification is not only feasible but offers the potential of enhancing risk assessment.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical high-risk; Conversion to psychosis; Glutamate; Risk calculator

Mesh:

Substances:

Year:  2019        PMID: 31522867      PMCID: PMC7065933          DOI: 10.1016/j.schres.2019.09.004

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  30 in total

1.  Reduced frontal glutamate + glutamine and N-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia.

Authors:  Tatsunobu Natsubori; Hideyuki Inoue; Osamu Abe; Yosuke Takano; Norichika Iwashiro; Yuta Aoki; Shinsuke Koike; Noriaki Yahata; Masaki Katsura; Wataru Gonoi; Hiroki Sasaki; Hidemasa Takao; Kiyoto Kasai; Hidenori Yamasue
Journal:  Schizophr Bull       Date:  2013-09-10       Impact factor: 9.306

2.  The Meaning of Glutamate and the Quest for Biomarkers in the Transition to Psychosis.

Authors:  Juan R Bustillo; Christopher E Gaudiot; Rhoshel K Lenroot
Journal:  JAMA Psychiatry       Date:  2019-02-01       Impact factor: 21.596

3.  Prefrontal and Striatal Gamma-Aminobutyric Acid Levels and the Effect of Antipsychotic Treatment in First-Episode Psychosis Patients.

Authors:  Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Xiangling Mao; Pablo León-Ortiz; Oscar Rodríguez-Mayoral; Helgi Jung-Cook; Rodolfo Solís-Vivanco; Ariel Graff-Guerrero; Dikoma C Shungu
Journal:  Biol Psychiatry       Date:  2017-10-10       Impact factor: 13.382

4.  The content of attenuated psychotic symptoms in those at clinical high risk for psychosis.

Authors:  Catherine Marshall; Erin Denny; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Scott W Woods; Elaine Walker; Jean Addington
Journal:  Psychiatry Res       Date:  2014-06-21       Impact factor: 3.222

5.  Associations of hippocampal metabolism and regional brain grey matter in neuroleptic-naïve ultra-high-risk subjects and first-episode schizophrenia.

Authors:  Igor Nenadic; Raka Maitra; Soumyajit Basu; Maren Dietzek; Nils Schönfeld; Carsten Lorenz; Alexander Gussew; G Paul Amminger; Patrick McGorry; Jürgen R Reichenbach; Heinrich Sauer; Christian Gaser; Stefan Smesny
Journal:  Eur Neuropsychopharmacol       Date:  2015-06-06       Impact factor: 4.600

6.  An Individualized Risk Calculator for Research in Prodromal Psychosis.

Authors:  Tyrone D Cannon; Changhong Yu; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Robert Heinssen; Clark D Jeffries; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Michael W Kattan
Journal:  Am J Psychiatry       Date:  2016-07-01       Impact factor: 18.112

7.  Prevalence and phenomenology of violent ideation and behavior among 200 young people at clinical high-risk for psychosis: an emerging model of violence and psychotic illness.

Authors:  Gary Brucato; Paul S Appelbaum; Michael D Masucci; Stephanie Rolin; Melanie M Wall; Mark Levin; Rebecca Altschuler; Michael B First; Jeffrey A Lieberman; Ragy R Girgis
Journal:  Neuropsychopharmacology       Date:  2018-12-27       Impact factor: 7.853

8.  Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume.

Authors:  James M Stone; Fern Day; Helen Tsagaraki; Isabel Valli; Mary A McLean; David J Lythgoe; Ruth L O'Gorman; Gareth J Barker; Philip K McGuire
Journal:  Biol Psychiatry       Date:  2009-06-25       Impact factor: 13.382

9.  Prefrontal NAA and Glx Levels in Different Stages of Psychotic Disorders: a 3T 1H-MRS Study.

Authors:  Edith Liemburg; Anita Sibeijn-Kuiper; Leonie Bais; Gerdina Pijnenborg; Henderikus Knegtering; Jorien van der Velde; Esther Opmeer; Annerieke de Vos; Jozarni Dlabac-De Lange; Lex Wunderink; André Aleman
Journal:  Sci Rep       Date:  2016-02-23       Impact factor: 4.379

10.  Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.

Authors:  Camilo de la Fuente-Sandoval; Francisco Reyes-Madrigal; Xiangling Mao; Pablo León-Ortiz; Oscar Rodríguez-Mayoral; Rodolfo Solís-Vivanco; Rafael Favila; Ariel Graff-Guerrero; Dikoma C Shungu
Journal:  Int J Neuropsychopharmacol       Date:  2015-09-12       Impact factor: 5.176

View more
  2 in total

1.  Measures of variability and precision in statistics: appreciating, untangling and applying concepts.

Authors:  Adam Ciarleglio
Journal:  BJPsych Adv       Date:  2020-06-18

2.  The Potential Clinical Utility of Auditory P3b Amplitude for Clinical High Risk.

Authors:  Xiaoli Liu; Haiyun Zhou; Changzhou Hu; Haihang Yu; Jucai Chu; Bifen Zhou
Journal:  Front Psychol       Date:  2022-06-16
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.